WHO ICTRP trial
A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate…
NL-OMON36032 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON36032 |
|---|---|
| Public title | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia |
| Scientific title | A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia - MK-143 |
| Primary sponsor | Merck Sharp & Dohme (MSD) |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Austria;Belgium;Czechia;Denmark;Finland;France;Germany;Italy;Lithuania;Netherlands ;Norway;Poland;Portugal;Spain;Sweden;United Kingdom |
| Conditions | primaire hypercholesterolemie of gemengde dyslipidemie Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia;Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia |
| Interventions | DOSAGE/DOSAGE FORM, ROUTE, AND DOSE REGIMEN All study medication products used in this study will be provided by the Sponsor. ERN/LRPT/SIM 1 g/10 mg and ERN/LRPT 1 g tablets will be in the same image. • ERN/LRPT/SIM combination will be… |
| Registration date | Oct 17, 2011 |
| Target size | 40 |
| Secondary IDs | 2011-001007-12;NCT01335997;NL37038.060.11 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: